Navigation Links
Raptor Pharmaceutical Expands Board of Directors
Date:10/1/2009

se stockholder value; that management's record of research, development and commercialization will serve as a strong foundation for Raptor's clinical trials and other development activities; that DR Cysteamine will receive marketing approval; and that any of Raptor's drug product programs will be successful. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Raptor's actual results to be materially different from these forward-looking statements. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in Raptor's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including the joint proxy statement/prospectus on Form S-4 filed with the SEC on August 19, 2009; Raptor's annual report on Form 10-K filed with the SEC on March 27, 2009; Raptor's quarterly report on Form 10-Q filed with the SEC on August 11, 2009; Raptor's wholly-owned subsidiary's, Raptor Pharmaceuticals Corp. ("RPC") Registration Statement on Form S-1, as amended, that was declared effective on August 7, 2008; RPC's annual report on Form 10-K filed with the SEC on October 30, 2008, as amended by that Form 10-K/A filed with the SEC on December 23, 2008; and RPC's quarterly report on Form 10-Q filed with the SEC on July 15, 2009, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to updat
'/>"/>
SOURCE Raptor Pharmaceutical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... MabVax Therapeutics Inc., a privately held clinical stage ... based therapies to address the unmet medical need of preventing ... in a Phase II clinical trial aimed at assessing the ... the recurrence of sarcoma. The clinical trial will enroll 126 ...
... NEW YORK , July 22 Reportlinker.com announces that a new market ... , , ... , http://www.reportlinker.com/p0240598/Wireless-Medical-Technologies-2007-2010.html ... Wireless Medical Technologies work on the basis of ...
Cached Medicine Technology:MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma 2MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma 3Reportlinker Adds Wireless Medical Technologies 2007-2010 2Reportlinker Adds Wireless Medical Technologies 2007-2010 3Reportlinker Adds Wireless Medical Technologies 2007-2010 4
(Date:4/23/2014)... developed a way to detect and measure cancer levels ... with tails of synthetic DNA., A team led by ... gold nanoparticles to target and bind to fragments of ... which can indicate the presence and stage of breast ... a cell can be determined by examining the specific ...
(Date:4/23/2014)... an important brain receptor has a dramatic effect against ... a University at Buffalo animal study has found. , ... a novel lead compound for treating cocaine addiction, for ... published as an online preview article in Neuropsychopharmacology ... RO5263397, severely blunted a broad range of cocaine addiction ...
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... accessible detection methods that can rapidly screen a ... single cell inside that population has been seriously ... , In the Royal Society of Chemistry journal ... he and his coworkers have developed a novel ... protein ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... , , , MOUNTAIN VIEW, Calif., July ... system solutions to acute healthcare facilities, today announced results for its second quarter ... results: Revenue for the second quarter of 2009 was $52.6 million, up ... million or 16.9% from the second quarter of 2008. , ...
... , LANCASTER, Pa., July 23 Eastern Insurance Holdings, ... to release financial results for the second quarter ended June 30, ... 2009. , , EIHI will ... a.m. ET to review the Company,s 2009 second quarter results. The ...
... in production is hampering efforts, but a nasal spray version ... million: that,s the number of doses of injectable swine flu ... October, with more doses coming in the form of a ... each person getting two doses spread a month apart, the ...
... , , PITTSBURGH, July 23 ... stopping in Pennsylvania throughout the week of July 27-31 at ... access information on programs that provide prescription medicines for free ... 8.2 percent -- compared to 5.1% a year ago -- ...
... dogma has been that bone-forming cells, derived from the body,s ... skeleton. However, new research shows that specialized cells in the ... from the bone marrow and that these bloodstream cells are ... skeleton. This work, published online this month in the journal ...
... , , NORTH BERGEN, N.J., July ... Industries Inc., today announced that it has filed a registration statement on ... proposed initial public offering of its common stock. Upon consummation of ... shares of common stock to be sold in the offering are expected ...
Cached Medicine News:Health News:Omnicell Announces Second Quarter 2009 Results 2Health News:Omnicell Announces Second Quarter 2009 Results 3Health News:Omnicell Announces Second Quarter 2009 Results 4Health News:Omnicell Announces Second Quarter 2009 Results 5Health News:Omnicell Announces Second Quarter 2009 Results 6Health News:Omnicell Announces Second Quarter 2009 Results 7Health News:Omnicell Announces Second Quarter 2009 Results 8Health News:Omnicell Announces Second Quarter 2009 Results 9Health News:Omnicell Announces Second Quarter 2009 Results 10Health News:Omnicell Announces Second Quarter 2009 Results 11Health News:Omnicell Announces Second Quarter 2009 Results 12Health News:Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results 2Health News:Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results 3Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 2Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 3Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 4Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 5Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 6Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 7Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 8Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 9Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 10Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 11Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 12Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 13Health News:U.S. Expects 160 Million Doses of Swine Flu Vaccine by October 14Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Pennsylvania Workers Hurt by Recession 4Health News:Bone from blood: Circulating cells form bone outside the normal skeleton, Penn study finds 2Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 2Health News:Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock 3
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... represents the latest breakthrough in visual ... the Humphrey Matrix will help you ... and assess treatment alternatives. Enhanced patient ... complete long-term glaucoma care for your ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... and disposable lens convenience for those with ... want crisp, clear vision with the convenience ... Vertex Toric lenses are manufactured using our ... a perfect edge on every lens. This ...
Medicine Products: